Novel Prostate Cancer Biomarkers Derived from Autoantibody Signatures()

BACKGROUND: Due to the low specificity of the prostate-specific antigen (PSA) assay and a high false positive rate, a large number of prostate cancer (PCA) biopsies are performed unnecessarily. Consequently, there is a need for new biomarkers that can identify PCA at any stage of progression while l...

Descripción completa

Detalles Bibliográficos
Autores principales: Schipper, Matthew, Wang, George, Giles, Nick, Ohrnberger, Jeanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415116/
https://www.ncbi.nlm.nih.gov/pubmed/25926076
http://dx.doi.org/10.1016/j.tranon.2015.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415116/
https://www.ncbi.nlm.nih.gov/pubmed/25926076
http://dx.doi.org/10.1016/j.tranon.2015.02.003

Ejemplares similares